Compare AbCellera Biologics Inc (ABCL) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs D R Horton Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while D R Horton Inc trades at $149.85 (market cap $44.16B). The key difference: D R Horton Inc is far larger — about 18.8× AbCellera Biologics Inc's market cap, and D R Horton Inc pays a 1.16% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DHI | |
|---|---|---|
Market Cap | $2.35B | $44.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $184.04 |
52-Week Low | $2.78 | $129.82 |
Enterprise Value | $1.99B | $48.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
D.R. Horton (DHI) trades at $155.72, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces headwinds from declining revenue and profit margins, with 2025 revenue dropping to $34.25B and net income falling to $3.59B. Recent earnings show mixed results with Q3 2025 missing expectations but Q4 2025 and Q1 2026 beating estimates. The company maintains strong operational cash flow of $3.42B despite a net cash outflow of $1.51B in 2025.
DHI presents a cautious opportunity with attractive valuation metrics (P/E 14.73, P/S 1.39) below sector averages, but faces significant housing market challenges. Analyst consensus leans neutral with 44% buy ratings and a $163.13 price target offering 4.8% upside. Key risks include housing market volatility, interest rate sensitivity, and competitive pressures in the homebuilding sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
